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 Platinum(II) anticancer medications essentially react with DNA forming kinks in 
the double helix of DNA and causing apoptosis.  It has also been noted that these 
anticancer medications react with methionine and cysteine in the body.  With the new 
discoveries of selenium containing amino acids including selenomethionine and 
selenocysteine, new research is ongoing to see what types of products can be formed 
from these amino acids.  Our research reacts [Pt(Met-S,N)Cl2] 2+  with selenomethionine 
to determine what types of products are produced.  Monochelates including [Pt(SeMet-
Se,N)Cl2] 2+  have formed two isomers, as well as other products that insinuate both 
selenomethionine and methionine binding with the platinum to form various [Pt(SeMet-
Se,N)(Met-S,N)] 2+  products.  When initially reacting 6 mM [Pt(Met-S,N)Cl2] 2+  with 3 
mM SeMet, the monochelates of both are produced without forming any free methionine 
which would suggest that there is free platinum in our solution creating the SeMet 
monochelate.  When adding additional SeMet to the solution the same products are 
formed that are created when reacting 6 mM [Pt(Met-S,N)Cl2] 2+  and 6 mM SeMet.  The 
1H NMR spectrum for these products imply a product of [Pt(SeMet-Se,N)(Met-S,N)] 2+.  
Also, reactions with [Pt(en)(ox)] 2+  and SeMet were conducted and produced various 
products at two different pH’s.  A [Pt(SeMet-Se,N)2] 2+  product was formed at lower pH 
and produced free ethylenediamine, however at a higher pH only [Pt(en)(SeMet-Se,N)] 2+  
was produced.
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I. INTRODUCTION 
 
A. History 
 According to the National Cancer Institute, around 1,638,910 human beings 
would be diagnosed with cancer, and 577,190 of them would die from cancer in the 
United States in 2012.1   On January 1, 2009, there were approximately 12,553,337 men 
and women alive that have had some form of cancer, which included people with cancer 
at that time or that had been cured of cancer at a previous point in their life.1   Odds are 
that most everyone in the U.S. population either knows someone directly or indirectly 
that has been affected by cancer.  Current anti-cancer medications have delivered results 
to patients that help them cope with the symptoms or allow the patient to go into 
remission.  One field of anti-cancer medications that is being studied is platinum(II) 
compounds; currently there are three platinum-containing FDA approved medications on 
the market for patients.  The first to ever be approved is Cisplatin, (cis-
diamminedichloroplatinum(II)).  Carboplatin, (cis-diammine-
cyclobutanedicarboxylatoplatinum(II)), is a second generation platinum-containing anti-
cancer medication and was developed with fewer side effects than that of cisplatin.  
Oxaliplatin, ((1R,2R-diamminocyclohexane) oxalatoplatinum(II)) is a third generation 
medication and works for patients that are resistant to cisplatin and carboplatin.   
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Figure 1.1) 
 
 
 
 
The cisplatin compound was actually first synthesized in 1845 by Michael 
Peyrone.3   Its anti-cancer activity wasn’t discovered until the 1960’s, and clinical trials 
intravenously in humans were completed by mid-1972.4   The clinical trials showed 
major advantages in testicular cancers, but also had produced renal toxicity in patients.4   
There were other toxicities that developed in other patients including ototoxicity, 
hematological toxicity, neuropathy and seizures.  Ultimately, the studies led to the 1978 
FDA approval of cisplatin for the treatment of testicular and ovarian cancer.  The drug 
also plays an important role in the treatment of other cancers, including, head and neck 
cancers, melanoma, bladder cancer and cervical cancers and many more other types of 
cancers.5 
During 1967 at Michigan State University, Dr. Barnett Rosenberg published an 
article in the Journal of Bacteriology stating that the platinum salt, ammonium 
hexachloroplatinate(II), was responsible for inhibiting cell division.2   A study was done 
in Dr. Rosenberg’s lab trying to see how an electric field would affect the growth process 
of bacteria, specifically E. coli.2   It was then found that a platinum salt that was being 
produced in the electric field inhibited cell division but had no effects on cell growth.2   
Structures of Cisplatin, Carboplatin and Oxaliplatin 3 contains the FDA approved 
platinum structures of Cisplatin, (cis-diamminedichloroplatinum(II)), Carboplatin, (cis-
diammine-cyclobutanedicarboxylatoplatinum(II)) and Oxaliplatin, ((1R,2R-
diamminocyclohexane) oxalatoplatinum(II)). 
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The platinum salt was identified to be [PtCl6]2-; the media containing the platinum salt 
and free ammonia that had also been exposed to ultraviolet radiation actually produces 
three different ligand platinum compounds, all with different effects on the bacteria.2   
Ammonium hexachloroplatinate(II) was one of the compounds that acted as a 
disinfectant and killed the bacteria.2   The second compound was [PtCl5NH3]- and seemed 
to have no effect on the bacteria.2   The last platinum compound formed was 
[PtCl4(NH3)2] and was the most stable species; this compound seemed to have an 
inhibition on cell division, but did not affect the cell growth.2  It was then decided that 
platinum salts should be studied to determine its biological effects.   
When it became obvious to Dr. Rosenberg’s lab that platinum metal has more 
than one oxidation state and there were different configurations being produced, cis and 
trans, four compounds were studied in mammalian cells.  Success was achieved with the 
[PtCl4(NH3)2] in the +2 oxidation state and with a cis configuration.  The thought was 
that the platinum compounds would inhibit cell growth in tumor cells but have no effect 
on the host animal.  There were four different platinum compounds that were tested in 
mice, shown below in Figure 1.2. 
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Figure 1.2) 
 
 
The compounds that showed the most successful anti-cancer activity were 
compounds 2 and 4.5   They were tested against Sarcoma-180 tumors in mice, and the 
tumors actually had shrunk in size due to the platinum compounds.5   The mice survived  
the treatment, and after 6 months of being treated they still showed no signs of cancer.5    
Based on these results, this was when compound two entered clinical trials in humans and 
showed promising results.  
 There are a few different mechanisms proposed for the anti-cancer activity of 
cisplatin, but the one that is most widely accepted proposes the drug reacts with DNA and 
causes apoptosis.5   When cisplatin enters the blood stream via intravenous exposure; the 
chloride ligands remain attached due to the high concentration of chloride in blood 
plasma.5   Once inside the cell the chloride ligands are replaced with water due to the 
concentration difference; the chloride concentration inside the cell is only 4 mM as 
opposed to 10 mM in blood plasma.5   Replacement of the chlorides creates a positively 
Structures of Platinum Compounds: (1) cis-Pt(IV)(NH3)2Cl4; (2) cis-Pt(II)(NH3)2Cl2; 
(3) Pt(II)(NH2CH2CH2NH2)Cl2; and (4) Pt(IV)(NH2CH2CH2NH2)Cl4. 
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charged compound that is now in its active form, and this form cannot readily leave the 
cell. From here the platinum compound enters the cell nucleus and reacts with DNA; 
usually two adjacent guanine residues on the double helix.5   Cisplatin can also bind to 
adjacent adenine-guanine residues.  Binding to adjacent residues causes the double helix 
to form a kink and become bent, which allows for the DNA binding protein to attach and 
either repair the DNA or initiate cell death.5   When the platinum compound attaches to 
DNA via guanine residues, specifically at the N7 position of the guanine residue, it 
typically forms a 1, 2 G-G intra-strand crosslink.5   Other possible products are formed 
including, 1, 2 A-G, and 1, 3 G-G intra-strand crosslinks, 1,2 and 1,3 G-G inter-strand 
crosslinks, and DNA-protein crosslinks.6   Below is a depiction showing the mechanism 
of binding with cisplatin and DNA. 
Figure 1.3) 
 
 
Mechanism of Action for Cisplatin: cisplatin reacting with the double helix and 
forming the various crosslinks causing apoptosis.3 
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B. Chemistry of Platinum Compounds 
Around the early 1900’s cisplatin’s geometry became the debate and topic for Alfred 
Werner’s theory of coordination chemistry.5   Werner’s theory showed two isomers that 
were formed, a cis and a trans, hence the name cisplatin and transplatin.5   He also 
suggested the square planar configuration correctly, and won the Nobel Prize for 
Chemistry in 1913.5  
Figure 1.4) 
 
 
Years later, scientists had studied how the structure contributed to the compounds 
anticancer activity.  Cleare and Hoeschele, developed the “structure-activity 
relationships,” and suggested what should be structurally required of a compound, as 
listed below:5 
• The compound should contain two amine groups in a cis position, because the 
trans geometry is inactive. 
• It should contain two leaving groups, also with a cis geometry relative to each 
other. 
• The ability of the leaving groups to be lost, contribute to the toxicity and 
activity of the compound.  It’s suggested that the leaving groups be easily 
removed. 
• The compound should also not have an overall charge. 
Structure of Cisplatin and Transplatin.  
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• The greater the activity of the compound, the fewer the alkyl substituents on 
the amine ligands, and each ligand should contain at least one proton. 
The general structure for these compounds should have a similar configuration to 
the structure in Figure 1.5: 
Figure 1.5) 
      
 
 
 
Any new platinum-containing anti-cancer drug to be considered for clinical trials 
must possess one of the following characteristics: to be delivered as an oral medication, 
generate reduced toxic side effects, and/or have activity against cancers with intrinsic or 
acquired resistance to cisplatin treatment.5   Any type of platinum compound that has 
deviated from the general structure will change the reactivity of the compound and how it 
reacts with DNA.   For example steric effects such as bulky amine ligands slow the 
reaction with DNA.7   A bulky amine ligand on a square planar platinum complex 
reduces the rate of the reaction with DNA and also slows down the binding to thiol 
containing proteins, which potentially reduces side effects and toxicity.7    
Since the drug must travel many places in the body before it ultimately reaches 
cellular DNA, there are many other prospective biomolecules with which the compound 
has the ability to react.   Platinum compounds have a high affinity for sulfur-containing 
Pt
H
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H
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X
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R
R
General Structure for Platinum(II) Compounds: X=leaving groups (two chloro 
groups or a bidentate malonate), and ligand R=H or an alkyl substituent.5 
 compounds, which is explained by the HSAB (Hard Soft/Acid Base) theory.  The HSAB 
theory states that “soft acids” tend to favor “soft base,” and likewise with hard acids and 
bases; therefore, the “soft” sulfur atom will donate a ligand to the “soft” platinum 
compound.  Potential targets that contain the sulfur atom are proteins that contain the 
amino acids methionine (Met) 
and the amino acids would be thermodynamically and kinetically favored, because of 
basic coordination chemistry knowledge.  
Figure 1.6)  
 
The HSAB theory helps explain why platinum
amino acids and proteins.  The theory was developed in the 1960’s by Ralph Pearson, and 
also known as the donor-acceptor theory.
ability to polarize, their size and 
polarizable, larger in size, and typically 
acids are electron acceptor
soft acids include Cu+, Au
8 
and cysteine (Cys).  In theory, these reactions of platinum 
 
 
(II) molecules react with certain 
9   Pearson categorizes acids and bases 
valence electrons.  Lewis acids and bases are e
have a lower charge (+1, +2).10   
s, and soft bases are electron donors.10   A few examples of 
+
, Ag+, Hg2+, and Pb2+; and for soft bases this includes, S
Structure of Cysteine and Methionine 
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2-
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have a higher charge (≥+3).
periodic table, Mg2+, Fe3
compounds that include ox
Therefore, when reacting a soft acid, it will prefer a soft base; likewise hard acids are 
preferential to hard bases.
 The donor-acceptor theory has been useful in helping researchers understand why 
metal ions in the body typically bind with some types
Cisplatin and other platinum
containing methionine and/or cysteine.  The platinum anti
the sulfur biomolecules are soft bases.  T
platinum, which is the electron acceptor.  There are other biomolecules that conta
selenium in place of sulfur,
donate electrons to platinum anti
Figure 1.7) 
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C. Reactions of Platinum Anti-Cancer Agents with Biomolecules 
After the platinum(II) drug is given intravenously to the patient, the drug enters the 
blood stream where it enters the cell, passes into the nucleus of the cell and reacts with 
DNA.  Before the medication enters the cell, there are many proteins available to react 
with the drug, and the reaction with DNA is thought to lead to cytotoxicity.  A question 
researchers have been debating is why does platinum react with sulfur residues, but 
ultimately ends up reacting with DNA.  One thought to the question is that the reaction of 
these platinum drugs with the amino acids cause toxicity and resistance.7   However, it 
should be noted that Pt-S bonding also has positive effects in the body; examples include 
preventing side effects, as well as using the Pt-S bond as optimal transport for the anti-
cancer medication throughout the body.7  Platinum drugs can react with thiol residues of 
cysteine-containing proteins, or the thioether residues of methionine-containing 
complexes.8 
Thioether residues are responsible for serving as a drug reservoir for platination at 
DNA inside the cell.  This is due to the concentration difference of the residues inside the 
cell which are much higher than outside the cell.8  As a drug reservoir this gives two new 
possible reaction pathways for DNA platination; either the instantaneous release of the 
platinum from sulfur then the reaction with DNA occurs, or the guanine N-7 group on 
DNA directly displaces the platinum from the sulfur.7   Thioether reactions serve as 
intermediates and are kinetically favored.8   However, the thioether bond can be broken 
by a thiol residue, the resulting bond is thermodynamically stable. Yet the bond is not 
easily broken, and contributes to toxicity and resistance of the anticancer medication.8 
11 
 
When the platinum binds to thiol containing groups, the Pt-S (thiol) bond contributes 
to the occurrence of toxicities with platinum(II) complexes as anticancer agents.8   
However, the Pt-S bond can be broken with the use of “rescue agents”, which are strong 
nucleophiles also containing sulfur.8    “Rescue agents” or “protecting agents” are sulfur 
containing compounds, administered with the Pt(II) anticancer medication.   A few of 
these rescue agents are sodium thiosulfate (STS), sodium diethyldithiocarbamate 
(Naddtc), thiourea, glutathione (GSH), cysteine (Cys), methionine (Met), N-
acetylcysteine, biotin and sulfathiazole.7   These compounds either prevent or terminate 
the Pt-S adducts in proteins and do not lower the anticancer activity of the Pt(II) 
complex.7   More research has been ongoing to determine the effects of these rescue 
agents and their potential uses.  Positive uses of these rescue agents include preventing 
side effects as well as optimal transport.7   For example, it was known that GSH is 
present in the cell has many functions, including detoxification of chemotherapeutic 
agents.  A clinical study with glutathione and cisplatin reported significantly reduced 
toxicity in ovarian cancer cases with cisplatin as treatment.8   
Other types of bonds can be formed with platinum(II) anticancer compounds, such as 
selenium containing amino acids.  Glutathione peroxidase and thioredoxin reductase 
(TrxR) are two enzymes that contain selenocysteine, and have been shown to react with 
platinum anticancer medications.11  Thioredoxin reductase contains a selenocysteine 
residue in its active site which is an easy target for platinum anticancer medications.13  
This enzyme has been shown to be inhibited due to reaction of platinum with 
selenocysteine; the uninhibited enzyme plays important roles in maintaining redox 
systems in the body.13  When the enzyme is inhibited, an increase of oxidized thioredoxin 
12 
 
(Trx) occurs, creating cellular conditions for stimulation of apoptosis.13   Selenocysteine 
is deliberately added to proteins, as opposed to selenomethionine which is arbitrarily 
inserted into proteins in place of methionine.11   Selenocysteine has a low pKa value and 
is a strong nucleophile, which makes it difficult for the amino acid to exist freely in cells, 
but is highly reactive when incorporated into proteins.14  Selenium containing compounds 
have been studied for their antioxidant effects as protecting agents for toxicity and 
resistance.11   Selenomethionine and S-methylselenocysteine showed increased survival 
rates in mice when given a toxic dose of cisplatin and oxaliplatin.11   
Disulfide bonds of oxidized glutathione (GSSG) have been studied for their 
participation in the redox systems in the body and are known to form during protein 
folding.16   Cysteine has the ability to partake in acid/base chemistry to form the disulfide 
bonds, either as a catalytic redox component or to convey structural stability.16    
Selenoglutathione (GSeSeG) was found to be more stable than GSSG and the 
selenocysteine residues were capable of oxidizing cysteine residues in unfolded proteins, 
which helps regain protein conformational stability upon folding.16       
Previous studies have shown that natural diselenide bonds have been created and in 
comparison to the disulfide bonds, diselenide bonds have a low redox potential.15   A 
similar study showed that the diselenide bond in selenocystine was studied for its 
reactivity with platinum anticancer drugs.  The results concluded that the diselenide bond 
could be split via the platinum structures, however, this meant that somehow redox 
reactions and/or reducing agents were used to complete this.14  One structure used to 
determine the ability to cleave the diselenide bond was [Pt(Met)Cl2] 2+.14   Results 
indicated that [GS-Sec]- and [GSSG]- were formed indicating that platinum drugs could 
13 
 
potentially interfere with the electron transfer process from reduced glutathione to 
glutathione peroxidase through the altering of the selenocystine residue therefore 
reducing the antioxidant ability of glutathione peroxidase.14  These studies are important 
to determine more information regarding these new selenium containing amino acids and 
their antioxidant effects in regards to platinum anticancer medications. 
Other studies have looked at how bulky amine ligands react with selenium containing 
amino acids, as well as competition studies of sulfur vs. selenium with the bulky platinum 
complexes.  Our investigation of cisplatin analogs with SeMet and Met showed the 
displacement of amine ligands due to the trans effect of selenium and sulfur ligation.11   
In the same study when bidentate or tridentate ligands were used, the displacement of 
amine ligands was less prevalent.11   One study showed that with the use of an 
ethylenediamine (en) ligand on a platinum complex, it reacts with SeMet and produces a 
bis-product of two selenomethionine residues joining the Pt(en) species forming 
[Pt(en)(SeMet-Se)2] 2+.11  Chelation eventually occurs and displaces the en ligand to form 
a bis-chelate product, ([Pt(SeMet-Se,N)2] 2+), and the remaining nitrogen on SeMet 
residues coordinate to platinum forming a six-membered ring.11 
 The research that is presented in this thesis will report the effects of using 
different leaving group ligands on bulky platinum(II) complexes and their reaction with 
selenomethionine and selenocysteine variants.  Particular amino acids that will be used 
are L-Methionine, Seleno-L-Methionine, Seleno-L-Cystine, and Se-
(Methyl)selenocysteine.  Our research will consist of the following platinum compounds: 
ethylenediamine platinum(II) (oxalate and dinitrate groups) ([Pt(en)(ox)] 2+  or 
[Pt(en)(NO3)2]2+).  These studies will also lead us to react the previous made [Pt(Met-
14 
 
S,N)Cl2] 2+  with selenomethionine to determine its reactivity.  We will use NMR 
spectroscopy, LC/MS, and HPLC to characterize our results.  An attempt to react the 
platinum compounds with the selenium-containing amino acids will be made at different 
pH ranges as well as with different stoichiometric variations.   
II. EXPERIMENTAL 
A Materials Used 
The following items were purchased from Sigma Aldrich: Sodium Chloride (NaCl), 
Potassium Tetrachloroplatinate(II) (K2PtCl4), Silver Nitrate (AgNO3), 
Dichloro(ethylenediamine)platinum(II) ((H2NCH2CH2NH2)PtCl2), Deuterium Oxide 
(D2O), and Se-(Methyl)selenocysteine Hydrochloride.  From Acros the following were 
purchased: Anhydrous Oxalic Acid, L-Methionine, L-Selenocystine, and L-
Selenomethionine.  
B NMR 
A JEOL Eclipse 500MHz Nuclear Magnetic Resonance was used to characterize 
products using deuterium oxide as a solvent.  When adjusting the pH of the different 
solutions made, 1.0% deuterated nitric acid and 1.0% sodium deuteroxide were used.  
Typically only a proton (1H) NMR scan was utilized; however, occasionally other scans 
were used including a HMQC (Heteronuclear Multiple Quantum Coherence), and a 
COSY (COrrelation SpectroscopY).  
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C LC/MS 
An Agilent 1100 HPLC coupled with a MSD (SL) ion-trap electrospray ionization 
spectrometer system was used to acquire the mass spectrometry data for these 
experiments.  The sample was introduced into the mass analyzer by the mobile phase 
solution of Methanol:Water (80:20) and injected at a flow rate of 200 µL min-1.  The 
voltage used for the electrospray needles was 3.5 kV, the capillary temperature was     
350 ˚C and recorded in negative ion mode.  The isotopic distribution pattern for each 
complex was simulated with the Isopro 3.0 program. 
D Synthesis of Platinum(II) Methionine Dichloride [Pt(Met)Cl2]2+ 
[Pt(Met)Cl2]2+ was made according to the method described by Norman et al.12  A 
solution containing potassium tetrachloroplatinate(II) (10.5 mg, 25.3 µmol), sodium 
chloride (4.5 mg, 77 µmol), and L-Methionine (3.5 mg, 23.3 µmol) were dissolved in 0.6 
mL of deuterium oxide.  The solution was mixed in an amber vial and heated in a water 
bath at 353 K for 10 minutes.  This produced a clear yellow solution with a pH of 1.6.  A 
6 mM solution of [Pt(Met)Cl2] 2+  was made as described by Liu et al.13  The solution was 
made by obtaining 142 µL of the [Pt(Met)Cl2] 2+  and diluted with 858 µL of deuterium 
oxide. 
E Synthesis of Platinum(II) Selenomethionine Dichloride [Pt(SeMet)Cl2] 2+ 
Two solutions of [Pt(SeMet)Cl2] 2+  were similarly made to that of [Pt(Met)Cl2]2+.  
The first solution was made using an amber vial and 10.5 mg of potassium 
tetrachloroplatinate, 4.9 mg of selenomethionine and 4.5 mg of sodium chloride in 0.6 
mL of deuterium oxide.  The solution was heated for ten minutes in a water bath at 353 
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K, and produced a yellow solution with a pH of 1.5.  To yield a 6 mM solution, 142 µL of 
the original sample was mixed with 858 µL of deuterium oxide.  The second solution was 
made the exact same way except there was no sodium chloride added, and the pH initially 
was 1.1, adjusting the pH to 9-10, using 1% sodium deuteroxide, the reactants finally 
dissolved in solution.  Again, 142 µL [Pt(Met)Cl2] 2+  was mixed with 858 µL of 
deuterium oxide and adjusted the pH to 7.0 to obtain a final 6 mM solution. 
F Preparation of Selenomethionine Solutions 
For a 6 mM solution of selenomethionine, 2.4 mg of the amino acid was dissolved in 
1.0 mL of deuterium oxide and pH was adjusted to 8.  Typically for a 1:2 ratio of 
platinum:SeMet, 500 µL of each solution was mixed together.  For a 3 mM solution of 
selenomethionine, 0.6 g of the amino acid was dissolved in 1.0 mL of deuterium oxide.  
Usually the pH of these solutions would eventually be adjusted either to around 3-4 or 7-
8, using 1.0% sodium deuteroxide and/or 1.0% deuterated nitric acid.   
G Preparation of Methionine, Selenomethionine and Platinum Compound 
This solution was made as two separate mixtures and then combining the mixtures 
together.  For the first vial, 2.35 mg of selenomethionine was added to 1.8 mg of 
methionine in 1.0 mL of D2O and stirred for around 2 hours.  The second solution was 
made with 10.5 mg (25.3 µmol) of potassium tetrachloroplatinate(II), 4.5 mg of sodium 
chloride in 1.0 mL of D2O and also stirred for about 2 hours.  Both mixtures were then 
combined into one vial having an initial pH of 1.8, then adjusted to 6.5.  After the pH was 
adjusted, the solution was left in an 80˚C heat bath overnight.  All solutions were mixed 
at an equimolar ratio of 25.3 µmol.    
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H Preparation of [Pt(en)ox]2+ 
This solution was made with 50 mg of silver oxalate, 50 mg of 
dichloro(ethylenediamine)platinum(II) in 30 mL of water and stirred for a few hours to 
ensure the reaction complete.  Next the solution was syringe filtered and placed on a 
rotovap and the ending product weight was 18.9 mg. 
I Reactions with [Pt(en)ox]2+ with Selenomethionine  
For a solution containing excess selenomethionine by weight, 2.0 mg of [Pt(en)ox] 2+  
was mixed in 1.0 mL of D2O, and in another vial 1.0 mg of selenomethionine was 
dissolved in 1.0 mL of D2O.  Both solutions were allowed to stir separately and then a 
500 µL aliquot of [Pt(en)ox] 2+  was added to the selenomethionine solution and resulted 
in a pH of 4.6.  Another sample with similar quantities of reagents was prepared except 
with this solution, the pH of both samples were raised to 7.0 before mixing and then after 
mixing samples together the pH was adjusted to 6.9.   
A sample containing excess platinum was mixed using 4.0 mg of [Pt(en)ox] 2+  in 1.0 
mL of D2O in one vial, and in a separate vial 1.0 mg of SeMet was mixed in 1.0 mL of 
D2O.  Both solutions were allowed to stir separately overnight and then the next day both 
solutions were mixed together and allowed to stir for around 3 hours and resulted in a pH 
of 5.0. 
III. RESULTS 
 Initially this project began by replicating Liu et al. paper, by trying to reproduce the 
selenocystine cleavage that they had accomplished.14   We were unable to do so, which 
lead us to reactions with selenomethionine.  Having previously worked with 
selenomethionine, products are simpler to assign using 1H NMR.  Using various 
 platinum(II) compounds with ammine ligands, such as [Pt(en)(D
(en=ethylenediamine) and [Pt(Me
tetramethylethylenediamine
ammine ligand will displace
products.11   For example, the ethyle
forming various products, while the Me
for only the formation of mo
Liu et al. paper, using selenomethionine and [Pt(Met)Cl
ratios forming several products.
A Reactions with [Pt(Met)Cl
 To begin, using a method 
K2PtCl4 was mixed with methionine to form [Pt(Met
LC/MS was used and a mass of 413 was observed in negative ion mode, which is 
comparable to that obtained via Liu et 
the two major isomers formed
1H 
α hydrogens 
Figure 3.1) 
18 
2O)2]2+ 
4en)(D2O)2] 2+, (Me4en= N,N,N’,N’-
) and having reacted with SeMet, typically the less bulky 
 from platinum allowing the formation of bischelate 
nediamine ligand does displace from platinum 
4en ligand does not become displaced and allows 
nochelate products.11   With these results and the results of 
2] 2+  were reacted a
 
2] and Selenomethionine 
previously described by Norman et al., a 1:1 mixture of 
-S,N)Cl2].  To confirm our results 
al. paper.  The following 1H NMR
, following the two structures for both isomers
NMR Spectrum of [Pt(Met-S,N)Cl2] 2+ 
Isomer A 
γ hydrogens 
t various 
 spectrum shows 
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Isomer B 
 β hydrogens 
 Figure 3.2) 
 
 
 
 
Figure 3.3)
 To determine the possible products that 
containing plausible products
products, adapting Norman et al
Mixing 10.5 mg of potassium tetrachloroplatinate
4.5 mg of sodium chloride in 0.6 mL of deuterium oxide in an amber vial and heating it 
in a heat bath at 80˚C for ten minutes gave a yellow solution with a pH of 1.5.  
µL of said sample and mixing it with 848 
spectrum: 
Structures of [Pt(Met
A (R configuration at S, envelope ring conformation) and 
the right structure is isomer B (
Hα 
Cl
H C3
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could be potentially produce
 were made.  This included making [Pt(SeMet)Cl
. method of making a 1:1 solution of [Pt(Met)Cl
(II), 4.9 mg of selenomethionine and 
µL of deuterium oxide produced the following 
-S,N)Cl2] 2+The left structure is isomer 
S configuration at S, 
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COO
2
-
Pt
Cl Cl
NS
H
H
COO
C3
2
 
d, solutions 
2] 2+  
2] 2+.  
Using 142 
-CH3 
Hβ 
-
 Figure 3.4) 
  
 The monochelate 
the methyl group is pointing.  This proton 
isomers forming in solution.  The figure below shows two possible structures for the 
SeMet monochelates: 
Figure 3.5) 
To further characterize products, an attempt to make the 
bischelate was made similarly to Norman et a
tetrachloroplatinate, 26.1 mg of selenomethionine (133 
1H NMR Spectrum
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products have two isomers possible, depending on which way 
NMR spectrum clearly depicts two major 
 
 
 
 
selenomethionine 
l.  Using 27.0 mg of potassium 
µM), and 6.0 mg of sodium 
Structures of [Pt(SeMet-Se,N)Cl2] 2+ 
Se-CH3 peaks 
 of [Pt(SeMet-Se,N)Cl2] 2+ 
Pt
Cl Cl
NSe
H
H
CO
C3
2H
COO
2
-
 
O-
 chloride was mixed with 0.6 mL of D
produced a clear yellow solution with a pH of 1.6.  The pH was adjusted to 6.5 and the 
solution turned colorless, the follo
 
Figure 3.7) 
 
  
1H NMR Spectrum
Expanded 
α-hydrogens of the 
three isomers 
Figure 3.6) 
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2O in a heat bath at 343 K for two minutes and 
wing spectrum shows the products produced:
 of [Pt(SeMet-Se,N)2] 2+ 
1H NMR Spectrum of [Pt(SeMet-Se,N)2] 2+ 
cis-[Pt(SeMet-Se,N)2-RR 
cis-[Pt(SeMet-Se,N)2-SS
cis-[Pt(SeMet-Se,N)2-R 
cis-[Pt(SeMet
γ-hydrogens of the 
three isomers 
β-hydrogens
three isomers
Additional 
β-hydrogens 
Se-CH3 peaks of the three 
different cis isomers formed
 
 
 
 
-Se,N)2-S 
 of the 
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 When assigning peaks to each of the isomers, we compared our spectra to those 
assigned previously.11   It has been previously noted that SeMet chelates have a stronger 
pi-accepting ability when compared to sulfur-containing chelates, and that a cis geometry 
is favored over a trans geometry.11   Typically, trans S-containing chelates have much 
broader signals in 1H NMR than Se-containing chelates.  Also, using LC/MS a mass of 
585 was recorded when using negative ion mode, which also corresponds to the 
bischelate product.  Other masses recorded was 621 which corresponds to [Pt(SeMet-
Se,N)(SeMet-Se,Cl)], and also a little less abundant was a mass of 460 which corresponds 
to the [Pt(SeMet-Se,N)(Cl2)], the monochelate. 
In the original paper by Liu et al., to obtain the various products a 6 mM, 
[Pt(Met)Cl2] 2+  was reacted with 3 mM selenocystine.  Our project used similar ratios, 6 
mM [Pt(Met)Cl2] 2+  with 3 mM SeMet.  First, a solution of the [Pt(Met)Cl2] 2+  was made 
and a separate solution of the SeMet was mixed, taking a 500 µL aliquot of both 
solutions, they were mixed and left overnight in a heat bath of around 70˚C.  The initial 
pH of the solution after mixing was 2.4, after leaving it in the heat bath overnight, not 
much had changed of the proton NMR peaks, so the pH was raised to 6.3 and put back 
into the heat bath for another night.  The reaction produced the following 1H NMR 
spectrum:  
 Figure 3.8)
 
When comparing [Pt(Met
Se,N)Cl2] 2+  peaks, selenium is typically up
the Norman et al. paper we determined the two small peaks around 2.38 
selenomethionine monochelates
the methionine monochela
however, from our spectrum we do not see any free methionine.  This lea
that there may be free potassium tetrachloroplatinate
which would not show up in a proton NMR spectrum.  Next, 0.3 mg of selenomethionine 
was added to the solution to see if the monochelate peaks would become more prominent.  
Allowing around 2 hours for the reaction to finish
solution.  The reaction was heated to 80
dropped the next day to around 2.8
been used up and produced the following spectrum:
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-S,N)Cl2] 2+  S-CH3 peaks to Se-CH3 [Pt(SeMet
field of sulfur peaks, and comp
ppm 
.  We expected the selenomethionine chelates to form
te would be knocked off and free methionine would be visible
(II) in our [Pt(Met)Cl
 there was still free selenomethionine in 
˚C in a water bath overnight, and the pH had 
.  It was noted that all of the selenomethionine
 
 of [Pt(Met-S,N)Cl2] 2+  with SeMet 
[Pt(SeMet)Cl
[Pt(Met)Cl
 
-
aring to that of 
were the 
 and 
; 
ds us to believe 
2] 2+  solution, 
 had 
2] peaks 
2] peaks 
  
Figure 3.9) 
 
The pH of the solution had dropped to 2.8
visible had now turned into two different sets of three peaks.
around the first three peaks refers
the other set of three peaks refer
peaks are formed, this suggests the formation of both Met and SeMet attaching to the 
platinum to form bischelates
the sample a mass of 574 
chelating while the other is only a monoadduct and a Cl
forming something like [Pt(SeMet
following figure depicts possible 
1H NMR Spectrum
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, and the previous peaks that were 
  The first black 
 to one product, while the second black 
s to another product.  Typically, when these types of 
 as [Pt(SeMet-Se,N)(Met-S,N)].  After performing LC/MS on 
(M-1) was observed which corresponds to either SeMet or Met 
-
 attached to the platinum, thus 
-Se,N)(Met-S)Cl] or [Pt(Met-S,N)(SeMet
structures produced in the reaction: 
 after additional SeMet added 
 
circle 
circle around 
-Se)Cl].   The 
 Figure 3.10) 
 
 Subsequently, a reaction consisting of 6 mM [Pt(Met)Cl
was mixed and the pH was adjusted up to 6.5 and produced the following spectrum:
Figure 3.11)
 
 
The reaction was placed in a
to 6.1, spectrum obtained 
1H NMR Sp
Structures of SeMet/Met Monoadduct/Monochelate
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2] 2+ and 6 mM SeMet 
n 80˚C water bath overnight and the pH had dropped 
after two weeks is shown in the following figure:
ectrum of 1:1 [Pt(Met-S,N)Cl2] 2+  & SeMet
S-
 
 
 
 
 
CH3  
Se-CH3 
 Figure 3.12) 
 
Figure 3.13) 
 
 After 2 weeks of the reaction, it still seems there is a little free methionine 
available, which would insinuate that t
allowing selenomethionine to bind
1H NMR Spectrum
Expanded 1
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he selenomethionine is displacing 
.  Expanding the spectrum, two sets of three peaks are 
 of 1:1 [Pt(Met-S,N)Cl2] 2+  & SeMet after 2 weeks
H NMR Spectrum of [Pt(Met)Cl2] 2+  & SeMet 
 
 
the methionine, 
 
Se-CH3 
S-CH3 
 very similar to each other and
after extra selenomethionine is added to the reaction.  This again implies that both 
selenomethionine and methionine
Se,N)(Met-S,N)].  After running LC/MS a mass of 538 (M
corresponds to both methionine and selenomethionine being chelated to the platinum.  
The following figure depicts the structure of th
Figure 3.14) 
  The succeeding result was 
while K2PtCl4 and NaCl were mixed in a separate vial, after said solutions were dissolved 
both vials were mixed all together.  
were mixed as one 12 mM solution, a separate solution of 12 mM selenomethionine and 
12 mM methionine were mixed.  T
of 1.8.  The pH of the mixture was adjusted to 6.5 and put in a
The next day the pH had dropped to 4.
Strucutre
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 also comparable to what the previous reaction turns into 
 are binding to the platinum to form [Pt(SeMet
-1) is observed which 
e plausible products formed:
 
formed by mixing SeMet and Met in one vial 
Potassium tetrachloroplatinate and sodium chloride 
he two solutions were mixed together resulting
n 80˚C heat bath overnight.  
0 and produced the following 1H NMR spectra:
 of [Pt(SeMet-Se,N)(Met-S,N)]2+ 
-
 
 in a pH 
  
  
Figure 3.16) 
  
The previous spectra show the monochelates formed by SeMet and Met giving 
[Pt(SeMet)Cl2] 2+  and [Pt(Met)Cl
mixture was put back into the 80
changed significantly.  The reaction observed for 
the reaction is shown in the following figure:
 
1H NMR Spectrum
Expanded 
Figure 3.15) 
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2] 2+.  To ensure that the reaction was complete, the 
˚C heat bath again overnight, and the pH had not 
the next week and the final spectrum of 
 
 of Competition Reaction with SeMet & Met
1H NMR Spectrum of Competition Reaction 
[Pt(Met)Cl2] 
[Pt(SeMet)Cl
 
 
 
2] 
  
Figure 3.17) 
 
B Reactions with [Pt(en)ox]
Oxaliplatin was a third generation platinum(II) anticancer medication approved that 
contains a DACH ligand (DACH=1,2
higher stability which leads to different reaction pathways than cisplatin and 
carboplatin.17   According to
the DACH ligand still coordinated to the platinum, when
When reacting 5’-GMP (GMP=guanosine monophosphate), with methionine and 
oxaliplatin, not only is the mon
two monoadducts of GMP
another, which insinuates a competitive reaction for the platinum between the two.  
1H NMR Spectrum
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 2+
  and Selenomethionine 
-diaminocyclohexane) giving the compound a 
 Küng et al., the S,N chelate of methionine is produced with 
 the oxalate is the leaving group.  
ochelate of methionine produced, but a species containing 
-N7 are also produced, but Met and GMP do not displace one 
 of Competition Reaction after 1 week
Se-
monochelate 
peaks
S-CH3 
monochelate 
peaks 
 
 
 
CH3 
 
 An oxaliplatin analog 
group was reacted in our research with selenomethionine.  These reactions took place at 
pH 4.0 and 7.0 with excess SeMet or excess platinum, and formed various products
The first experiment began with excess platinum in solution relative to 
selenomethionine at a pH of around 4
NMR spectrum:  
Figure 3.18) 
 
Initially we see peaks corresponding to the monoadduct of selenomethionine and the 
oxalate ligand, as well as the Se,N monochelate with the en ligand still attached as well.  
There is also an impurity around 2.2 ppm from the deuter
another spectrum was produced
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containing an ethylenediamine ligand and an oxalate leaving 
.0.  This experiment produced the following 
ium oxide used.  Five days later 
 
 of [Pt(en)(ox)]2+  & SeMet at pH 4.0 
[Pt(en)(SeMet-Se)ox]
[Pt(en)(SeMet-Se,N)] 
.   
1H 
 
Impurity 
 
 Figure 3.19) 
 
After five days the monoadducts of SeMet have now turned into the monochelate
forming [Pt(en)(SeMet-Se,N
that around 3.3 ppm, a small peak has begun showing which corresponds to the free 
ethylenediamine ligand.  This reaction had initially begun at a pH of 5
the pH had dropped to 3.9
coordination to the platinum
The next reaction consisted of excess SeM
produced the following spectra after four hours of the r
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)] 2+, as well as the remaining impurities.  We can also note 
.0 and after 5
, due in part to the deprotonation of the amine nitrogen upon 
. 
et and had an initial pH of 4.6
eaction being mixed:
 of [Pt(en)(ox)]2+  & SeMet after 5 
 
 
 
 days 
 and 
 
  
Figure 3.20) 
 
At pH 4.0 with excess selenomethionine
ethylenediamine produced initially here tha
also can see a SeMet bischelate having been produced here as well.  Another spectrum 
was produced after approximately 20 hours of 
the following figure: 
Figure 3.21) 
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, it is obvious that there is more free 
n with excess platinum at the same pH.  We 
the initial reaction been mixed shown in 
 of [Pt(en)(ox)]2+  with excess SeMet at pH 4
 
Free SeMet 
[Pt(en)(SeMet-Se,N
[Pt(SeMet-Se,N)2] 
 
Free SeMet 
[Pt(en)(SeMet-
[Pt(SeMet-Se,N)2] 
 of [Pt(en)(ox)]2+ & excess SeMet at 
pH 4.0 after 20 hours 
 
 
.0 
)] 
Se,N)] 
 In the above NMR spectrum we see the peak for the free ethylenediamine has 
grown and there is still free selenomethionine.  The SeMet monochelate is still being 
produced as well as the SeMet bischelate.  
ethylenediamine to the pH difference when chelation occurs.  When SeMet is chelating it 
loses a hydrogen atom causing the pH to drop.  
The next experiment consisted of the same conditions as the prior experiment 
except the pH was adjusted to 7
1.0 mL of D2O and the pH was adjusted to 7
was mixed in 1.0 mL of D
allowed to stir for 2 hours separately and then a 
was mixed with the entire SeMet solution.   Again the solution was allowed to stir for a 
few hours and the pH was again adjusted to 7.0
spectrum: 
Figure 3.22) 
 
At a higher pH there are 
to that at a lower pH.  For instance, there is no free ethylenediamine ligand available, 
1H NMR Spectrum
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We can attribute the additional free 
 
.0.  For this reaction 2.0 mg of [Pt(en)ox]
.0, while in a separate vial 1.0 mg of SeMet 
2O and the pH was also adjusted to 7.0.  Both solutions were 
500 µL aliquot of the platinum solution 
 and produced the following NMR 
quite a few differences in the spectrum when compared 
Free SeMet 
[Pt(en)(SeMet-Se,N)] 
 of [Pt(en)(ox)]2+  & excess SeMet at pH 7
 2+
  was mixed in 
 
.0 
 although the SeMet monochelate is still being produced.  This ag
due to the SeMet favoring monochelate formation at higher pH
reaction the spectrum still looks the same with no free ethylenediamine being produced 
and only the SeMet monochelate being produced as shown in the following figure:
Figure 3.23) 
 
Even after only a few days the pH had only drop
insinuates that only the SeMet bischelate can be formed under these conditions at a low 
pH of around 4.0, due to the SeMet becoming 
 
 Confirmed metabolites of patients taking 
monochelate, so potentially selenomethionine could be a potential metabolite of pat
since platinum kinetically
injecting rats with cisplatin, Pt(II)
1H NMR Spectrum
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ped from 6.9 to 5.3
deprotonated at a high pH.
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 prefers reactions with selenium rather than sulfur.
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and relatively quickly, and potentially selenomethionine complexes would be produced 
as well.12 
 This research was typically monitored via 1H NMR spectroscopy, and to confirm 
our results we used LC/MS.  Once the results from the Liu et al. paper could not be 
replicated we determined to study selenomethionine, as products were much easier to 
assign and we had previously studied reactions with selenomethionine and platinum.    
 Using Norman et al. method, we were able to reproduce the methionine 
monochelate, and we used a similar strategy to form the selenomethionine monochelates 
as well.  Reacting potassium tetrachloroplatinate(II) and selenomethionine with sodium 
chloride at a 1:1 ratio produces the selenomethionine monochelate.  When reacting the 
same reagents but at a 1:2 ratio, there are three different isomers of the bischelate formed; 
RR, RS, and SS.  In order to confirm our results we used LC/MS and obtained a mass of 
585 which corresponded to the [Pt(SeMet-Se,N)2] 2+, and the monochelate produced a 
mass of 460 (M-1) giving the product [Pt(SeMet-Se,N)Cl2] 2+.  When comparing the 
SeMet monochelate to that of Norman et al. Met monochelate, the ratio of isomers is 
relatively similar.12  Also, when comparing the SeMet and Met bischelates, the most 
stable isomer formed is the cis product with both Met and SeMet bischelates, while only 
small traces of trans isomers were produced only in the Met bischelate.11,12   This is of 
interest because a complex conveyed as the trans isomer of [Pt(Met-S,N)2] 2+  was 
isolated in patients treated with cisplatin, but the cis isomer could be potentially 
explained due to selenium having an increased pi-accepting ability over sulfur.11,12 
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 When trying to react 6 mM [Pt(Met-S,N)Cl2] 2+  with 3 mM SeMet, various 
products are formed.  When both monochelates of Met and SeMet were formed with this 
solution, this would suggest that there was free potassium tetrachloroplatinate available 
for the SeMet to react with thus forming the monochelate.  In this reaction there was 
never any free methionine produced, which would also suggest that there is free platinum 
for the SeMet to react with.  Free platinum from K2PtCl4 would not show up in a proton 
NMR, and having previously checked the [Pt(Met-S,N)Cl2] 2+  sample, there wasn’t any 
free methionine, so it was assumed that everything was done reacting.  However, the 
results suggested otherwise by the formation of both monochelates. 
 After adding additional SeMet to the solution, similar peaks were produced when 
compared to the reaction of 6 mM [Pt(Met-S,N)Cl2] 2+  and 6 mM SeMet.  The equimolar 
solution produced various peaks, producing two sets of three peaks and the pairs of peaks 
were extremely similar to one another suggesting that some sort of species consisting of a 
methionine, selenomethionine bonding to a platinum atom being produced.  The peaks 
from the 6 mM [Pt(Met-S,N)Cl2]2+  and 3 mM SeMet with the extra addition of SeMet 
after a few days resulted in comparable peaks to that of the equimolar ratio solution 
which would again suggest a species containing both methionine and selenomethionine 
joining a platinum atom.  Using LC/MS to help confirm our results after adding the 
additional selenomethionine a mass of 574 was produced which is consistent with a 
species consisting of both methionine and selenomethionine having been connected to 
one platinum atom, because either SeMet or Met is chelated to platinum while the other is 
only a monoadduct.  With LC/MS one cannot determine specifically which is chelated 
and which is not.  However, we tried to compare alpha hydrogens of both a methionine 
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monochelate and a selenomethionine monochelate, but the resolution from the NMR 
spectrum is not good enough to come to a definitive conclusion on which is chelated and 
not.   
 When both amino acids were mixed together in one vial, while the platinum and 
sodium chloride were mixed in a separate vial and later both vials mixed together, it was 
never thought that only monochelates would form.  After looking at the NMR spectrum 
and noticing only monochelates developing, it was observed that one isomer was formed 
preferentially.  The methionine monochelate in previous papers has already been 
determined that isomer A (Figure 3.2) is favored due to the methyl group that is pointed 
away from the rest of the structure creating less steric hindrance.  When looking at the 
monochelates formed by selenomethionine, it could be determined that one isomer is also 
favored, and could be concluded that it is isomer B (Figure 3.2).  This could also be 
concluded due to the methyl group having less steric hindrance when pointed away from 
the rest of the structure. 
 When reacting selenomethionine with [Pt(en)ox] 2+  various products are formed 
and some products are not formed at a higher pH.  When using excess SeMet at a pH of 
4.0 the SeMet bischelate is formed through a [Pt(en)(SeMet-Se)2] 2+  intermediate and 
then releases free ethylenediamine.  This would mean that the second SeMet is competing 
with the amine group from the first bonded SeMet, and would insinuate that the amine is 
less protonated making the Se a better ligand rather than the amine ligand.  A reaction 
scheme below shows the formation of the SeMet bischelate: 
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Figure 4.1) 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 However, using the same conditions and only changing the pH up to 7.0, there is 
no free ethylenediamine produced and no SeMet bischelate formed, only the SeMet 
monochelate is produced.  This would suggest again that at a higher pH the amine group 
Reaction Scheme forming SeMet bischelate at pH 4.0 
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on the first bonded SeMet is more deprotonated making it a better ligand this time rather 
than a second Se of SeMet.   
Figure 4.2) 
 
 
 
 
 
 
  
  
  
 Also, when using excess platinum but at a low pH, a small amount of 
ethylendiamine is available, but a SeMet monochelate is produced, and the SeMet 
monoadduct is formed as well.  The following reaction scheme depicts the products 
formed at a pH 4.0 with excess platinum:   
  
 
NH2 NH2
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+
O
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O
NH2 NH2
O O
O O
Pt
Pt
+ excess SeMet
pH 7
Reaction Scheme forming SeMet monochelate at pH 7.0 
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Figure 4.3) 
 
 
 
 
 
 
 
 
 
 
  
 Since the SeMet bischelate is formed at a low pH when using [Pt(en)ox]2+, this 
can be explained due to the SeMet becoming deprotonated when adding another SeMet to 
the platinum releasing a hydrogen in relatively acidic conditions and additionally 
dropping the pH even further allowing chelation to occur.  At a pH of 4.0 this occurs 
relatively quickly, and doesn’t occur at all in pH of 7.0.  When using excess of platinum 
at a low pH the SeMet bischelate does not form and there is very little free 
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Reaction Scheme forming SeMet monochelate at pH 4.0 
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ethylenediamine ligand available when compared to using excess SeMet at pH 4.0.  
While many papers have reported a [Pt(dach)(Met-S,N)] 2+  product, a bischelate using 
the ligand DACH has not been produced, and may could be due to the previous studies 
being done at a pH of around 7.0, while it seems that the bischelate can be produced at a 
lower pH instead of a higher pH. 
V. CONCLUSION 
 These metabolites are interesting as both selenomethionine and methionine are 
found in the body and once a patient takes a platinum(II) anticancer medication, these 
results could be similar to ones formed inside the body.  The fact that a sulfur and 
selenium containing amino acid can bind to potentially the same platinum forming 
similar products at relatively similar rates is intriguing and what would happen with these 
products in the body are interesting.   
 These results show that a methionine and selenomethionine can bind to the same 
platinum molecule.  The selenomethionine monochelate is also formed when reacting at a 
1:1 ratio; the bischelate was not formed with any of these reactions when methionine and 
selenomethionine are both present in solution. 
   There is still further work to be done with these results such as confirming which 
amino acid is chelated versus which is not and which isomers are formed.  Using these 
results and trying similar experiments using selenocystine or cysteine would be another 
plausible area to explore.   
 In concluding the results with the reactions of [Pt(en)ox] 2+  and SeMet a 
bischelate is formed at a lower pH and is not formed at a higher pH.  This would suggest 
that at a higher pH the monochelate is only formed due to the amine nitrogen on the first 
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coordinating SeMet adduct being more deprotonated and making a better ligand rather 
than another SeMet being coordinated and then forming the bischelate.  While at a lower 
pH it is just the opposite and suggests a competition for the amine group of the first 
coordinated SeMet adduct and the second SeMet-Se, making the Se of the second SeMet 
a better ligand than the amine group of the first SeMet.   
 Many of these results are of interest due to the known metabolites that have been 
produced in patients taking platinum(II) medications.  In summary many new products 
have been synthesized and formed at different pH’s which gives new insight into trying 
various platinum compounds at lower pH’s to see if bischelates can be formed.   
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